local infiltration of liposomal bupivacaine — Competitive Intelligence Brief

local infiltration of liposomal bupivacaine (local infiltration of liposomal bupivacaine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (amide class). Area: Anesthesia / Pain Management.

marketed Local anesthetic (amide class) Voltage-gated sodium channels Anesthesia / Pain Management Small molecule

Target snapshot

local infiltration of liposomal bupivacaine (local infiltration of liposomal bupivacaine) — TriHealth Inc.. Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission, with extended duration due to liposomal encapsulation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
local infiltration of liposomal bupivacaine TARGET	local infiltration of liposomal bupivacaine	TriHealth Inc.	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
Lamotrigine (drug)	Lamotrigine (drug)	MaineHealth	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels; glutamate release inhibition
Lamotrigine Generic "A"	Lamotrigine Generic "A"	University of Cincinnati	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Pregabalin and Oxcarbazepine	Pregabalin and Oxcarbazepine	Ju Seok Ryu	marketed	Anticonvulsant combination; Gabapentinoid and aromatic antiepileptic drug	Alpha-2-delta calcium channel subunit (pregabalin); voltage-gated sodium channels (oxcarbazepine)
Carbamazepine (Tegretol)	Carbamazepine (Tegretol)	Korean Epilepsy Society	marketed	Anticonvulsant; sodium channel blocker	Voltage-gated sodium channels
intravenous lidocaine (IVL)	intravenous lidocaine (IVL)	Ciusss de L'Est de l'Île de Montréal	marketed	Local anesthetic; Class IB antiarrhythmic	Voltage-gated sodium channels
Quetiapine and Topiramate	Quetiapine and Topiramate	University of Cincinnati	marketed	Atypical antipsychotic + anticonvulsant mood stabilizer combination	D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (amide class) class)

1. Ain Shams University · 2 drugs in this class
2. Başakşehir Çam & Sakura City Hospital · 2 drugs in this class
3. TriHealth Inc. · 2 drugs in this class
4. Centre of Postgraduate Medical Education · 2 drugs in this class
5. Bozyaka Training and Research Hospital · 2 drugs in this class
6. Complejo Hospitalario Universitario de Granada · 1 drug in this class
7. Clinique Saint-Jean, Bruxelles · 1 drug in this class
8. Hospital Clínico Universitario de Valencia · 1 drug in this class
9. Fundacion Clinica Valle del Lili · 1 drug in this class
10. Federal University of Minas Gerais · 1 drug in this class